Skip to main content
Clinical Trials/ACTRN12621001109897
ACTRN12621001109897
Recruiting
未知

The effect of nocturnal supplemental oxygen for the management of obstructive sleep apnoea in patients with fibrotic interstitial lung disease

Dr Yet Hong Khor0 sites54 target enrollmentAugust 23, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr Yet Hong Khor
Enrollment
54
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 23, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Dr Yet Hong Khor

Eligibility Criteria

Inclusion Criteria

  • 1\.Age greater than or equal to 18 years
  • 2\.Able to give written informed consent
  • 3\.A multidisciplinary diagnosis of fibrotic interstitial lung disease of any aetiology
  • 4\.Suspected obstructive sleep apnoea or confirmed diagnosis of obstructive sleep apnoea using overnight polysomnography

Exclusion Criteria

  • 1\.Use of or eligible for long\-term oxygen therapy
  • 2\.Use of respiratory stimulants or depressants
  • 3\.Stable health condition (defined as hospitalisation for acute medical conditions) in the last 4 weeks before screening
  • 4\.Significant co\-existing chronic obstructive pulmonary disease (defined as FEV1/FVC \<60% on the most recent lung spirometry or extent of emphysema greater than extent of fibrosis on the most recent CT chest)

Outcomes

Primary Outcomes

Not specified

Similar Trials